Ten-year hemoglobin A1c trajectories and outcomes in type 2 diabetes mellitus: The Diabetes & Aging Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
AIMS To classify trajectories of long term HbA1c values in patients after diagnosis of Type 2 diabetes and examine each trajectory's associations with subsequent microvascular and macrovascular events and mortality. METHODS Longitudinal follow-up of 28,016 patients newly diagnosed with Type 2 diabetes. Latent growth mixture modeling to identify ten-year HbA1c trajectories. Cox proportional hazards models to assess how HbA1c trajectories were associated with events (microvascular and macrovascular) and mortality. RESULTS We identified 5 HbA1c trajectories: “low stable” (82.5%), “moderate increasing late” (5.1%), “high decreasing early” (4.9%), “moderate peaking late” (4.1%) and “moderate peaking early” (3.3%). After adjusting for average HbA1c, compared to the low stable trajectory, all non-stable trajectories were associated with higher incidences of microvascular events (hazard ratio (HR) range, 1.28 (95% CI, 1.08-1.53) (high decreasing early) to 1.45 (95% CI, 1.20-1.75) (moderate peaking early). The high decreasing early trajectory was associated with an increased mortality risk (HR, 1.27 (95% CI, 1.03-1.58)). Trajectories were not associated with macrovascular events. CONCLUSIONS Non-stable HbA1c trajectories was associated with greater risk of microvascular events and mortality. These findings suggest a potential benefit of early diabetes detection, prioritizing good glycemic control, and maintaining control over time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“The differential findings for microvascular and macrovascular events are consistent with the temporal findings from the UKPDS (UK Prospective Diabetes Study (UKPDS) Group, 1998a, 1998b; Holman et al., 2008).”
InfluentialValidation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572 · cited 2×
“Among patients with type 2 diabetes mellitus, a primary strategy for reducing complications is controlling hyperglycemia (AmericanDiabetes Association, 2014).”
Ethnic disparities in diabetic complications in an insured population
Karter, A. J. (2002) · JAMA · doi:10.1001/jama.287.19.2519 · Cited by 840 · cited 1×
“The Kaiser Permanente Northern California Diabetes Registry (Registry) is a well-characterized, longitudinal cohort of all patients with diabetes mellitus cared for at Kaiser Permanente (Kaiser) (Karter et al., 2002; Karter et al., 2004).”
Self-citationRiddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406 · cited 2×
“%) were associated with a 64% increased mortality rate after 3 years (Riddle et al., 2010).”
Hirakawa, Y., Arima, H., Zoungas, S., Ninomiya, T., Cooper, M., Hamet, P., Mancia, G., Poulter, N., Harrap, S., Woodward, M., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0199 · Cited by 363 · cited 2×
“Greater glycemic variability has been associated with increased risk of microvascular and macrovascular events and mortality in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and small-medium cohort studies in Taiwan, Japan, Italy and Spain (Ma et al., 2012…”
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
Glycemic Variability: Both Sides of the Story
Ceriello, A., & Kilpatrick, E. S. (2013) · Diabetes Care · doi:10.2337/dcs13-2030 · Cited by 111
Temporal Trends in Recording of Diabetes on Death Certificates
McEwen, L. N., Karter, A. J., Curb, J. D., Marrero, D. G., Crosson, J. C., & Herman, W. H. (2011) · Diabetes Care · doi:10.2337/dc10-2312 · Cited by 63
Self-citation
Cited by
Laiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Self-citationCardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0677-0 · Cited by 222
Sidorenkov, G., van Boven, J. F. M., Hoekstra, T., Nijpels, G., Hoogenberg, K., & Denig, P. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13332 · Cited by 24
“There are a number of earlier studies looking at HbA1c trajectories in general.(21,22) Although these studies did not look at the HbA1c response specifically after insulin initiation, the trajectories of change”
ResultCahn, A., Zuker, I., Eilenberg, R., Uziel, M., Tsadok, M. A., Raz, I., & Lutski, M. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3485 · Cited by 9
Metadata
- Authors
- Laiteerapong, N., Karter, A. J., Moffet, H. H., Cooper, J. M., Gibbons, R. D., Liu, J. Y., Gao, Y., & Huang, E. S.
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 31
- Issue
- 1
- Pages
- 94-100
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- OpenAlex
- W2497946522
- Cited by
- 101
- References
- 10
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.